PMC Links for Books (Select 2827750) - PMC

Links from Books

Items: 1 to 20 of 36

<< First< Prev

Page of 2

Select item 87181751.

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE

Akito Hata, Isamu Okamoto, Naoki Inui, Morihito Okada, Masahiro Morise, Kohei Akiyoshi, Masayuki Takeda, Yasutaka Watanabe, Shunichi Sugawara, Naofumi Shinagawa, Kaoru Kubota, Toshiaki Saeki, Tomohide Tamura

J Clin Oncol. 2022 Jan 10; 40(2): 180–188. Published online 2021 Nov 18. doi: 10.1200/JCO.21.01315

PMCID:: PMC8718175

Abstract Article PDF–440K

Select item 76572062.

Risk factors of chemotherapy‐induced nausea and vomiting: Index for personalized antiemetic prophylaxis

Ikuo Sekine, Yoshihiko Segawa, Kaoru Kubota, Toshiaki Saeki

Cancer Sci. 2013 Jun; 104(6): 711–717. Published online 2013 Apr 16. doi: 10.1111/cas.12146

PMCID:: PMC7657206

Abstract Article PDF–227K

Select item 70666863.

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy

Lee Schwartzberg, Rudolph Navari, Rebecca Clark‐Snow, Ekaterine Arkania, Irena Radyukova, Kamal Patel, Daniel Voisin, Giada Rizzi, Rita Wickham, Richard J. Gralla, Matti Aapro, Eric Roeland

Oncologist. 2020 Mar; 25(3): e589–e597. Published online 2019 Dec 8. doi: 10.1634/theoncologist.2019-0527

PMCID:: PMC7066686

Abstract Article PDF–654K

Select item 65540294.

Classification of the Acute Emetogenicity of Chemotherapy in Pediatric Patients: A Clinical Practice Guideline

Edric Paw Cho Sing, Paula D. Robinson, Jacqueline Flank, Mark Holdsworth, Jennifer Thackray, Jason Freedman, Paul Gibson, Andrea D. Orsey, Priya Patel, Robert Phillips, Carol Portwine, Jennifer L. Raybin, Sandra Cabral, Lillian Sung, L. Lee Dupuis

Pediatr Blood Cancer. Author manuscript; available in PMC 2019 Jun 6.

Published in final edited form as: Pediatr Blood Cancer. 2011 Aug; 57(2): 191–198. Published online 2011 Apr 4. doi: 10.1002/pbc.23114

PMCID:: PMC6554029

Abstract Article PDF–822K

Select item 58341445.

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

L Zhang, S Lu, J Feng, A Dechaphunkul, J Chang, D Wang, S Chessari, C Lanzarotti, K Jordan, M Aapro

Ann Oncol. 2018 Feb; 29(2): 452–458. Published online 2017 Oct 28. doi: 10.1093/annonc/mdx698

PMCID:: PMC5834144

Abstract Article PDF–371K

Select item 53444506.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy, Heshan Liu, Steven F. Powell, Madhuri Bajaj, Leah Dietrich, David Biggs, Jacqueline M. Lafky, Charles L. Loprinzi

N Engl J Med. Author manuscript; available in PMC 2017 Mar 9.

Published in final edited form as: N Engl J Med. 2016 Jul 14; 375(2): 134–142. doi: 10.1056/NEJMoa1515725

PMCID:: PMC5344450

Abstract Article PDF–698K

Select item 53217087.

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, Igor Bondarenko, Tomasz Sarosiek, Cristina Oprean, Servando Cardona-Huerta, Vincent Hansen, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Hope Rugo

Support Care Cancer. 2017; 25(4): 1127–1135. Published online 2016 Nov 24. doi: 10.1007/s00520-016-3502-x

PMCID:: PMC5321708

Abstract Article PDF–689K

Select item 47089558.

Characterization of Dronabinol Usage in a Pediatric Oncology Population

Joshua J. Elder, Holly M. Knoderer

J Pediatr Pharmacol Ther. 2015 Nov-Dec; 20(6): 462–467. doi: 10.5863/1551-6776-20.6.462

PMCID:: PMC4708955

Abstract Article PDF–160K

Select item 43110699.

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

Harry Raftopoulos, William Cooper, Erin O’Boyle, Nashat Gabrail, Ralph Boccia, Richard J. Gralla

Support Care Cancer. 2015; 23(3): 723–732. Published online 2014 Sep 2. doi: 10.1007/s00520-014-2400-3

PMCID:: PMC4311069

Abstract Article PDF–648K

Select item 416152610.

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy

Mary Lou Affronti, Joseph Bubalo

Cancer Manag Res. 2014; 6: 329–337. Published online 2014 Sep 5. doi: 10.2147/CMAR.S68102

PMCID:: PMC4161526

Abstract Article PDF–261K

Select item 407175511.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

P. J. Hesketh, G. Rossi, G. Rizzi, M. Palmas, A. Alyasova, I. Bondarenko, A. Lisyanskaya, R. J. Gralla

Ann Oncol. 2014 Jul; 25(7): 1340–1346. Published online 2014 Mar 7. doi: 10.1093/annonc/mdu110

PMCID:: PMC4071755

Abstract Article PDF–218K

Select item 407175412.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

M. Aapro, H. Rugo, G. Rossi, G. Rizzi, M. E. Borroni, I. Bondarenko, T. Sarosiek, C. Oprean, S. Cardona-Huerta, V. Lorusso, M. Karthaus, L. Schwartzberg, S. Grunberg

Ann Oncol. 2014 Jul; 25(7): 1328–1333. Published online 2014 Mar 5. doi: 10.1093/annonc/mdu101